In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
Healis Therapeutics is a single-asset biotech with a candidate that CEO Eric Finzi believes can treat a range of mental illnesses. The asset, botulinum toxin A, or BoNT/A, is not patented, but the company has several methods of use patents for a range of illnesses. Finzi explains how facial injections of BoNT/A can treat major depressive disorder, post-traumatic stress disorder, and other conditions by preventing frowning and targeting the amygdala.
Timestamps:
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.
